<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of lethal opioid overdose in the community</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of lethal opioid overdose in the community</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of lethal opioid overdose in the community</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Phillip Coffin, MD, MIA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew J Saxon, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H544614055"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Drug overdose, principally due to opioids, is rising in many developed countries; in the United States, drug overdose has been the leading cause of injury-related death since 2009, with opioid overdose alone the leading cause since 2016 [<a href="#rid1">1</a>].</p><p>Strategies proposed to reduce opioid overdose and subsequent mortality include treatment of opioid use disorder with opioid agonist therapies (and possibly other medications) [<a href="#rid2">2</a>], provision of <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> to lay persons [<a href="#rid3">3</a>], and establishment of safe consumption sites [<a href="#rid4">4</a>]. At least two behavioral interventions have also shown promise in reducing overdose events in pilot randomized trials [<a href="#rid5">5,6</a>]. Increased caution in prescribing of opioids for pain management, while important in preventing cases of opioid use disorder, has uncertain effects on overdose mortality [<a href="#rid7">7</a>].</p><p>This topic describes prevention of lethal opioid overdose in the community. The epidemiology, pharmacology, screening, assessment, diagnosis, and treatment of opioid use disorder are discussed separately. Management of intoxication and withdrawal from opioids are also discussed separately, as is abuse of prescription drugs.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/99647.html" rel="external">"Opioid use disorder: Psychosocial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/99647.html" rel="external">"Opioid use disorder: Psychosocial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7808.html" rel="external">"Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults", section on 'Clinical features of overdose'</a> and  <a class="medical medical_review" href="/z/d/html/126633.html" rel="external">"Pharmacologic management of chronic non-cancer pain in adults", section on 'Opioids'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">"Prescription drug misuse: Epidemiology, prevention, identification, and management"</a>.)</p><p></p><p class="headingAnchor" id="H544614808"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H4263390788"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>Opioid overdose deaths are responsible for more than 30 percent of all drug-related deaths worldwide [<a href="#rid8">8</a>]. In the United States, the number of opioid-involved overdose deaths more than doubled, from 25,052 to 50,178 between 2013 and 2020 [<a href="#rid9">9,10</a>].</p><p>The rise in lethal opioid overdoses has been seen with prescription opioids, heroin, and synthetic opioids other than <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>Mortality from overdoses involving opioid analgesics more than tripled from 1999 to 2013 [<a href="#rid11">11-14</a>], stabilized from 2010 to 2013 [<a href="#rid11">11-14</a>], and continued to slowly rise into 2017 [<a href="#rid15">15</a>], notwithstanding declines in the rate of opioid prescribing. Since then, overdose deaths involving opioid analgesic have slowly declined, and increasingly are also attributed to synthetic opioids (eg, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>) [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Synthetic opioids (eg, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>) are responsible for most opioid overdoses (73 percent of opioid overdose deaths in 2020) [<a href="#rid10">10</a>]. This rise has been driven by illicitly manufactured fentanyl. Fentanyl is increasingly present in other street drugs, including cocaine, methamphetamine, and counterfeit pills, and is believed to be related to increased rates of overdose death involving those substances as well [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The majority of overdose deaths involving opioids also involve other drugs, such as cocaine, methamphetamine, alcohol, or benzodiazepines [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H544615086"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Overdose can occur at any time with any opioid agonist. A prior overdose is the strongest predictor of a future overdose and of overdose death [<a href="#rid17">17</a>]. Risk factors associated with overdose include [<a href="#rid18">18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Co-occurring use of sedatives or alcohol, which are also respiratory depressants; epidemiologic data also suggest elevated risk with consumption of cocaine. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1">As an example, in a retrospective analysis of 315,428 privately insured patients prescribed opioid medication, concurrent use of both opioid and benzodiazepine medications was associated with an increased risk of an emergency room visit or inpatient admission for opioid overdose compared with patients receiving an opioid but not a benzodiazepine (adjusted odds ratio 2.14, 95% CI 2.05-2.24) [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recent abstinence – A period of abstinence increases the risk of overdose from relapse by lowering the patient's tolerance to opioids. A dose that would have had minimal effects on the patient when physiologically dependent can cause overdose in the abstinent patient. Patients may be at risk due to abstinence after release from incarceration, during hospitalization or after discharge, or following medically supervised withdrawal or abstinence-based treatment of opioid use disorder [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of nonprescribed opioids, particularly when injected [<a href="#rid20">20</a>]. Variations in the (often unknown) purity and potency of heroin account for approximately 15 percent of the variation in overdose fatality [<a href="#rid21">21</a>]. Compared with injection of prescribed opioid analgesics, injection of heroin or <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> is approximately two and eight times as likely to result in overdose, respectively [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among prescription opioid users, higher prescribed doses [<a href="#rid23">23</a>] and discontinuation of long-term opioid therapy [<a href="#rid24">24</a>] .</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Co-occurring pulmonary disease or sleep apnea [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A genetic predisposition to the respiratory depressive effects of opioids [<a href="#rid26">26</a>].</p><p></p><p>Social determinants of health are often associated with increased risk of overdose, possibly mediated by unstable life situations and interruptions in opioid tolerance [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H178654"><span class="h1">CLINICAL FEATURES OF OVERDOSE</span><span class="headingEndMark"> — </span>Clinical features of opioid intoxication and overdose are discussed in detail separately, as is the pharmacology of opioids. Education on the clinical features of overdose is discussed below. (See  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults", section on 'Pharmacology and cellular toxicology'</a> and  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults", section on 'Clinical features of overdose'</a> and <a class="local">'Overdose education'</a> below.)</p><p class="headingAnchor" id="H544615120"><span class="h1">COMMUNITY-BASED INTERVENTION</span><span class="headingEndMark"> — </span>Opioid overdose prevention involves education and provision of take-home <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> to patients at risk of an overdose, their caregivers, and household members. Broad access to naloxone has been recommended by the United States surgeon general. Programs that provide sterile syringes and safe disposal equipment to high-risk populations are well positioned to educate their clients about opioid overdose and offer naloxone to reverse overdoses. As of 2019, 94 percent of syringe access programs in the United States had initiated naloxone distribution programming [<a href="#rid28">28</a>]. Participants are taught to recognize risk factors for overdose, signs and symptoms of overdose, and how to administer naloxone.</p><p class="headingAnchor" id="H3948867050"><span class="h2">Who should receive?</span><span class="headingEndMark"> — </span>Based on guidelines from the United States Centers for Disease Control and Prevention [<a href="#rid29">29</a>], the US Food and Drug Administration (FDA) [<a href="#rid30">30</a>], and other sources, we suggest that education and take-home <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> be provided to patients with any of the following risk factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Any nonprescribed drug use, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Opioid use, particularly those:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Receiving or discontinuing treatment for opioid use disorder, including medication or behavioral therapies</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>At risk of decreased tolerance due to recent abstinence, including release from prison or medically supervised opioid withdrawal</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of cocaine, methamphetamine, or pills purchased on the street, due to frequent presence of illicitly manufactured <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> in these drugs or counterfeit pills</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suspected opioid use disorder (mild, moderate, or severe) [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Receiving prescribed opioids and any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Receiving ≥50 <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> mg equivalents daily of prescribed opioids [<a href="#rid29">29</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Concomitant use of other sedating drugs or medications, such as benzodiazepines [<a href="#rid29">29</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Any history of a substance use disorder [<a href="#rid29">29</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Any history of overdose from opioids [<a href="#rid29">29</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk of witnessing an opioid overdose, if such witnessing and intervening is legally protected (see the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpdaps.org%2Fdatasets%2Flaws-regulating-administration-of-naloxone-1501695139&amp;token=mZoJOddu3zuLPjOW9%2FnaTNcik1HYN8Toun2hDLcKBg%2F2wKuAfoyRJh44Nax90deuCNSDfxg3wqND5KSwWLpy9aX%2F0dJCv5LsNc3Wdikpfvg%3D&amp;TOPIC_ID=99945" target="_blank">Prescription Drug Abuse Policy System</a> for legal protections in the United States).</p><p></p><p>Misuse of prescribed opioids is also described separately, as are risk factors for overdose among patients treated with opioids for chronic pain. (See  <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">"Prescription drug misuse: Epidemiology, prevention, identification, and management", section on 'Opioid analgesics'</a> and  <a class="medical medical_review" href="/z/d/html/93598.html" rel="external">"Use of opioids in the management of chronic non-cancer pain"</a>.)</p><p class="headingAnchor" id="H178788"><span class="h2">Components</span></p><p class="headingAnchor" id="H178800"><span class="h3">Overdose education</span><span class="headingEndMark"> — </span>Many patients do not recognize opioid-induced respiratory depression requiring emergency medical care as “overdose,” but instead consider this to be an adverse reaction to medications [<a href="#rid31">31</a>]. Participants in the preventive intervention receive education to help them identify people who are more likely to overdose, to recognize clinical signs of opioid overdose, and to intervene to prevent mortality:</p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for overdose:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of nonprescribed opioids</p><p class="bulletIndent2"><span class="glyph">•</span>Injection of opioids</p><p class="bulletIndent2"><span class="glyph">•</span>Use of other sedating substances with opioids</p><p class="bulletIndent2"><span class="glyph">•</span>Use of opioids after periods of reduced use or abstinence from opioids</p><p class="bulletIndent2"><span class="glyph">•</span>Certain comorbidities, such as lung disease or obstructive sleep apnea</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recognition of overdose:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonresponsive</p><p class="bulletIndent2"><span class="glyph">•</span>Decreased or stopped breathing or heart rate</p><p class="bulletIndent2"><span class="glyph">•</span>Blue or purple cast to fingernails or fingertips</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Response to overdose:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Try to arouse patient by administering a firm sternal rub. (See  <a class="medical medical_review" href="/z/d/html/5104.html" rel="external">"Stupor and coma in adults", section on 'Level of consciousness'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If in respiratory distress or not breathing, administer <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>. (See <a class="local">'Formulations'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Call emergency medical services (EMS):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>911 in the United States</p><p class="bulletIndent3"><span class="glyph">-</span>112 common in European Union countries</p><p class="bulletIndent3"><span class="glyph">-</span>000 in Australia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Perform rescue breathing, chest compressions, or cardiopulmonary resuscitation (CPR), depending on respondent's skills and guidance from emergency dispatch. (See  <a class="medical medical_review" href="/z/d/html/272.html" rel="external">"Adult basic life support (BLS) for health care providers", section on 'Ventilations'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stay with the patient for at least three hours or until help arrives.</p><p></p><p class="bulletIndent2">Emergency medical services differ in whether they routinely transport all opioid overdose survivors to a hospital emergency department following <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> administration. Some allow paramedics to send home patients who respond fully following an uncomplicated overdose of a short-acting opioid.</p><p></p><p class="bulletIndent2">In the absence of a paramedic or treating clinician, a patient should always go to the emergency department after <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>. Patients who overdosed on a long-acting opioid may initially respond to naloxone but relapse when the antagonist wears off. Naloxone may also precipitate withdrawal, which could lead to further opioid use and possible overdose, and thus the patient should be observed to ensure comfort and safety.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Place person on their side to prevent aspiration after vomiting.</p><p></p><p>Participant education takes approximately 5 to 10 minutes. <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fstore.samhsa.gov%2Fsites%2Fdefault%2Ffiles%2Fsma18-4742.pdf&amp;token=w0SURrInU8T5WClQlsoqZoaIrSpZxupc04wkeI6KJD%2BLaU8Z%2FFO5xfrIqHm5xuE%2BYwZ%2Birfqn0XOBXWWMJIakWSlWFgXNQKFYLsikwo6%2FSE%3D&amp;TOPIC_ID=99945" target="_blank">A toolkit</a> developed by the Substance Abuse and Mental Health Services Administration in the United States provides lay educational material on the preventive intervention [<a href="#rid32">32</a>].</p><p>Materials to assist healthcare providers in prescribing, dispensing, or educating about <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> are available at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fprescribetoprevent.org%2F&amp;token=GyJT9c8WpK0j7jmBKltXBQ0yaGRMYA5c2hHI35Wih9orlnPnh0CWzyE4uwnI5h9Y&amp;TOPIC_ID=99945" target="_blank">PrescribeToPrevent website</a>.</p><p>Limited data suggest that education on overdose recognition and response may be effective. A clinical trial of a brief education (5 to 10 minutes) in 10 persons with current or former opioid misuse found that, compared with no education, participants receiving education were more likely to recognize opioid overdose, identify scenarios where <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> was indicated, and report higher perceived competency in recognition [<a href="#rid33">33,34</a>].</p><p class="headingAnchor" id="H178806"><span class="h3">Community-based naloxone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">Naloxone</a> is an opioid antagonist that rapidly reverses the effects of opioid overdose. A 4 mg naloxone intranasal spray is available to purchase over the counter; some insurers may cover this product even when purchased over the counter [<a href="#rid35">35</a>].</p><p>While prescribing <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> to a patient who uses opioids has been determined to be within the realm of usual practice [<a href="#rid36">36</a>], most states in the United States have also passed legislation authorizing prescribers to provide naloxone through standing orders and/or to potential overdose witnesses, and protecting those who administer naloxone from penalties for practicing medicine without a license. See the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncsl.org%2Fresearch%2Fcivil-and-criminal-justice%2Fdrug-overdose-immunity-good-samaritan-laws&amp;token=vlZ3%2BAQ3MvxposLBDHVPHm5p9CDIvxr0nYHkWPIqIzZ9iEd%2FuF5fV3VcOfyU1OwQ9vgnX4wuL1CiSvOBrdfaucgax8I9KvmcPJHcXaj0M8Ag9tK0AElMO46IHG6yPeH8&amp;TOPIC_ID=99945" target="_blank">National Conference of State Legislatures</a> for details on Good Samaritan laws.</p><p class="headingAnchor" id="H544615212"><span class="h4">Formulations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Naloxone</strong><strong> intranasal spray</strong> – <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">Naloxone</a> intranasal spray is available in a dispenser that delivers a premeasured dose of 4 mg (Narcan) or 8 mg (Narcan or Kloxxado). The 4 mg intranasal spray is available over the counter. Our preference is to prescribe the 4 mg spray due to fewer side effects and lack of known benefit to the higher dose. The 8 mg intranasal spray was approved by the FDA as the 4 mg intranasal spray previously approved often required a second dose [<a href="#rid37">37</a>]. However, data from naloxone distribution programs suggest that bystanders will often administer any doses that they have available. It is uncertain if both doses of the 4 mg spray were used because a higher dose was needed or because the time waiting for the drug to take effect prompted a second dose.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">Naloxone</a> is dispensed as two doses; repeat doses may be necessary if respiratory depression continues or recurs prior to EMS arrival. Individuals are advised to wait three to five minutes after first dose before administering another dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Naloxone</strong><strong> injection</strong> – Injectable <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> for use in the community is available as prefilled syringes and kits:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> 5 mg/0.5 mL prefilled syringe (Zimhi) has been FDA-approved for intramuscular administration by nonmedical caregivers 12 years or older. However, until further studies support its efficacy and safety, we typically do not recommend using this product as the dose vastly exceeds doses for which any data are available [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">Naloxone</a> “kits” may include a prefilled syringe (2 mg/mL), syringe cartridge, or naloxone vials (0.4 mg/mL) prescribed with syringe and needle appropriate for intramuscular or subcutaneous administration. These injectable forms of naloxone were designed for use by medical personnel in the facility or field setting, however they have been used for decades by bystanders trained in naloxone distribution programs [<a href="#rid39">39,40</a>].</p><p></p><p class="headingAnchor" id="H2248531231"><span class="h4">Administration</span><span class="headingEndMark"> — </span>The standard dose of <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> for out-of-hospital opioid overdose reversal is 0.4 mg to 2 mg. The higher dose is associated with severe withdrawal symptoms and reluctance to seek medical assistance in the event of overdose. Intranasal naloxone at 4 mg/0.1 mL produces a blood concentration similar to 2 mg injected in healthy volunteers but may produce a lower blood concentration in real world circumstances and has generally been well tolerated.</p><p>The increase in opioid overdose mortality associated with <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> has led some to suggest that <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> is not effective in reversing fentanyl overdose. However, this increase in mortality may be explained by the known higher risk of overdose from fentanyl use compared to other opioids [<a href="#rid22">22</a>]. This is likely due a shorter window to bystander response due to a much more rapid progression from use to respiratory and cardiac arrest after fentanyl use compared to other opioids [<a href="#rid41">41</a>]. Once an overdose has progressed to cardiac arrest, naloxone is insufficient to reverse the event, regardless of the dose or formulation.</p><p class="headingAnchor" id="H544615246"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Analyses of survey, population, and mortality data, though methodologically limited, have reported associations between distribution of <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> and reductions in opioid overdose death in communities. These data suggest that many opioid overdoses have been reversed with lay use of injected or intranasal naloxone. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>An analysis compared mortality rates related to opioid overdose in communities that did and did not implement overdose education and <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> distribution programs, finding that communities implementing the program had a relative reduction in adjusted mortality rates. The results suggested a "dose-dependent" trend in which the more naloxone distributed in a given community, the greater the relative reduction in opioid overdose mortality (adjusted relative risk of 0.73 in communities with 1 to 100 naloxone enrollments per 100,000 population, and 0.57 in communities with &gt;100 enrollments) [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of evaluations of <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> studies found that lay administration of naloxone was associated with significantly increased odds of recovery compared with no lay naloxone administration (odds ratio 8.58, 95% CI 3.90-13.25) [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A survey of United States programs that distribute <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> for lay use reported that 644 sites had provided naloxone to 152,283 laypersons and received reports of 26,463 reversals from 1996 to 2014 [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An observational study of <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> prescription to patients who were prescribed long-term opioids for chronic pain found that receipt of naloxone was associated with a 47 percent decline in opioid-related emergency department visits over the ensuing year [<a href="#rid44">44</a>].</p><p></p><p>These studies were conducted prior to FDA-approval of the autoinjector or nasal spray.</p><p class="headingAnchor" id="H544615312"><span class="h4">Adverse effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">Naloxone</a> has been used safely by emergency department personnel and first responders for many decades. Two types of adverse events are seen:</p><p class="bulletIndent1"><span class="glyph">●</span>Side effects of abrupt reversal of opioid effects include nausea, vomiting, tachycardia, elevated blood pressure, and tremulousness; these are typically transient in patients without underlying cardiovascular or pulmonary disease. Serious adverse effects may include seizures and cardiac arrest, which have been observed rarely. Studies of lay reversal have reported relatively low rates of adverse events. As an example, a study of 399 reversals reported vomiting in 13 percent, anger or "dope sickness" in 9 percent, and seizure-like activity in &lt;1 percent [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reversal of overdose effects by <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> may be temporary. The drug's half-life is brief. Antagonism may wane before opioids are fully eliminated from the person's body, leading to recurrence of respiratory depression. This may not be a problem clinically with short-acting opioids like heroin; large studies of patients reversed with naloxone by paramedics and then released without transport to the hospital have found little to no evidence of recurrence of overdose leading to fatality [<a href="#rid46">46,47</a>].</p><p></p><p class="headingAnchor" id="H544615336"><span class="h4">Follow-up</span><span class="headingEndMark"> — </span>Because <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>'s overdose-reversing effects can wear off, those who may administer naloxone should be advised to seek medical help and stay with the overdosed person for three hours. Some patients may need repeated doses of naloxone, particularly if long-acting opioids such as <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> are involved.</p><p class="headingAnchor" id="H2653319438"><span class="h3">Nalmefene</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="135038" href="/z/d/drug information/135038.html" rel="external">Nalmefene</a> is another opioid antagonist approved as an injection or an intranasal spray for emergency treatment of known or suspected opioid overdose. We advise against nalmefene for community reversal of opioid overdose among opioid-experienced persons due to the expected need for additional medical management, as well as a potential negative impact on the willingness of bystanders to administer reversal agents in the future. While there are decades of experience with lay administration of <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>, there is no such experience with nalmefene. Furthermore, while the half-life of naloxone is 90 minutes, the half-life of nalmefene is 11 hours, thus any withdrawal symptoms would be prolonged and require additional medical management. The potential role of nalmefene in the emergency department setting is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults", section on 'Basic measures and antidotal therapy'</a>.) </p><p>The initial dose is given intravenously, intramuscularly, subcutaneously, or intranasally depending on the formulation. The nasal spray comes in a 2.7 mg dose. If no effect is seen, additional doses may be administered every two to five minutes until help arrives. Dosing for the injection formulation is 0.5 mg as initial dose and 1 mg may be given two to five minutes later if no response to initial dose. Side effects, which largely consist of opioid withdrawal signs and symptoms, include nausea, vomiting, hypertension, and tachycardia.</p><p class="headingAnchor" id="H1793708267"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113643.html" rel="external">"Society guideline links: Opioid use disorder and withdrawal"</a>.)</p><p class="headingAnchor" id="H544615657"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Drug overdose, principally due to opioids, is rising in many developed countries; in the United States, for example, it has been the leading cause of injury-related death since 2009. The incidence of opioid overdose increased dramatically between 1990 and 2017. Opioid overdose is defined as opioid-induced respiratory depression such that assistance is needed to revive the person. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overdose education</strong> – The risk of overdose should be discussed with all patients who use opioids. Providers should clarify that "overdose" does not necessarily imply use of an abnormally large amount of opioids, but instead that respiratory depression from opioids that can occur for many reasons. (See <a class="local">'Overdose education'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Who should receive?</strong> – We suggest that education and take-home <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> be provided to patients with any of the following risk factors (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>) (see <a class="local">'Who should receive?'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Any nonprescribed drug use, particularly:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Receiving or discontinuing treatment for opioid use disorder, including medication or behavioral therapies</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>At risk of decreased tolerance due to recent abstinence from opioids, including release from prison or medically supervised opioid withdrawal</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Use of cocaine, methamphetamine, or pills purchased on the street, due to frequent presence of illicitly manufactured <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> in these drugs</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suspected opioid use disorder (mild, moderate, or severe) [<a href="#rid29">29</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Receiving prescribed opioids and any of the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Receiving ≥50 <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> mg equivalents daily of prescribed opioids [<a href="#rid29">29</a>]</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Concomitant use of other sedating drugs or medications, such as benzodiazepines</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Any history of a substance use disorder</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Any history of overdose from opioids</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Risk of witnessing an opioid overdose, if such practice is legally protected (see the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpdaps.org%2Fdatasets%2Flaws-regulating-administration-of-naloxone-1501695139&amp;token=mZoJOddu3zuLPjOW9%2FnaTNcik1HYN8Toun2hDLcKBg%2F2wKuAfoyRJh44Nax90deuCNSDfxg3wqND5KSwWLpy9aX%2F0dJCv5LsNc3Wdikpfvg%3D&amp;TOPIC_ID=99945" target="_blank">Prescription Drug Abuse Policy System</a> for legal protections in the United States)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Community-based interventions</strong> – Intervention to prevent opioid overdose is comprised of education and provision of take-home <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> to patients at risk of an overdose, their caregivers, and household members. Participants are taught to recognize risk factors for overdose and signs and symptoms of overdose, and how to administer naloxone. (See <a class="local">'Overdose education'</a> above and <a class="local">'Formulations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Take-home <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> is available in easy-to-administer forms, using an intranasal spray or autoinjector to deliver fixed doses.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The usual adult dose of <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> is 0.4 mg when injected intravenously, intramuscularly, or subcutaneously; or 4 mg of the 4 mg/0.1 mL concentration when administered intranasally.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Repeat doses may be necessary if respiratory depression continues or recurs prior to emergency medical services arrival.</p><p></p><p class="headingAnchor" id="H544615998"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Eric Strain, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Opioid overdose. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/drugoverdose/index.html (Accessed on June 19, 2018).</li><li><a class="nounderline abstract_t">Babu KM, Brent J, Juurlink DN. Prevention of Opioid Overdose. N Engl J Med 2019; 380:2246.</a></li><li><a class="nounderline abstract_t">Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013; 346:f174.</a></li><li><a class="nounderline abstract_t">Marshall BD, Milloy MJ, Wood E, et al. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet 2011; 377:1429.</a></li><li><a class="nounderline abstract_t">Bohnert AS, Bonar EE, Cunningham R, et al. A pilot randomized clinical trial of an intervention to reduce overdose risk behaviors among emergency department patients at risk for prescription opioid overdose. Drug Alcohol Depend 2016; 163:40.</a></li><li><a class="nounderline abstract_t">Coffin PO, Santos GM, Matheson T, et al. Behavioral intervention to reduce opioid overdose among high-risk persons with opioid use disorder: A pilot randomized controlled trial. PLoS One 2017; 12:e0183354.</a></li><li><a class="nounderline abstract_t">Pitt AL, Humphreys K, Brandeau ML. Modeling Health Benefits and Harms of Public Policy Responses to the US Opioid Epidemic. Am J Public Health 2018; 108:1394.</a></li><li class="breakAll">World Health Organization. International Classification of Diseases for Mortality and Morbidity Statistics. 2019. 11th revision.</li><li><a class="nounderline abstract_t">Gladden RM, O'Donnell J, Mattson CL, Seth P. Changes in Opioid-Involved Overdose Deaths by Opioid Type and Presence of Benzodiazepines, Cocaine, and Methamphetamine - 25 States, July-December 2017 to January-June 2018. MMWR Morb Mortal Wkly Rep 2019; 68:737.</a></li><li class="breakAll">Provisional Drug Overdose Death Counts. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm (Accessed on October 28, 2021).</li><li><a class="nounderline abstract_t">Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015; 372:241.</a></li><li><a class="nounderline abstract_t">Unick GJ, Rosenblum D, Mars S, Ciccarone D. Intertwined epidemics: national demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993-2009. PLoS One 2013; 8:e54496.</a></li><li><a class="nounderline abstract_t">Hedegaard H, Chen LH, Warner M. Drug-poisoning deaths involving heroin: United States, 2000-2013. NCHS Data Brief 2015; :1.</a></li><li><a class="nounderline abstract_t">Rudd RA, Paulozzi LJ, Bauer MJ, et al. Increases in heroin overdose deaths - 28 States, 2010 to 2012. MMWR Morb Mortal Wkly Rep 2014; 63:849.</a></li><li class="breakAll">Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants — United States, 2015–2016. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/mmwr/volumes/67/wr/mm6712a1.htm?s_cid=mm6712a1_w#T2_down (Accessed on June 19, 2018).</li><li><a class="nounderline abstract_t">Lim JK, Earlywine JJ, Bagley SM, et al. Polysubstance Involvement in Opioid Overdose Deaths in Adolescents and Young Adults, 1999-2018. JAMA Pediatr 2021; 175:194.</a></li><li><a class="nounderline abstract_t">Coffin PO, Tracy M, Bucciarelli A, et al. Identifying injection drug users at risk of nonfatal overdose. Acad Emerg Med 2007; 14:616.</a></li><li><a class="nounderline abstract_t">Darke S, Zador D. Fatal heroin 'overdose': a review. Addiction 1996; 91:1765.</a></li><li><a class="nounderline abstract_t">Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ 2017; 356:j760.</a></li><li><a class="nounderline abstract_t">Darke S, Hall W. Heroin overdose: research and evidence-based intervention. J Urban Health 2003; 80:189.</a></li><li><a class="nounderline abstract_t">Darke S, Hall W, Weatherburn D, Lind B. Fluctuations in heroin purity and the incidence of fatal heroin overdose. Drug Alcohol Depend 1999; 54:155.</a></li><li><a class="nounderline abstract_t">Latimer J, Ling S, Flaherty I, et al. Risk of fentanyl overdose among clients of the Sydney Medically Supervised Injecting Centre. Int J Drug Policy 2016; 37:111.</a></li><li><a class="nounderline abstract_t">Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015; 162:276.</a></li><li><a class="nounderline abstract_t">Oliva EM, Bowe T, Manhapra A, et al. Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ 2020; 368:m283.</a></li><li><a class="nounderline abstract_t">Chaparro LE, Furlan AD, Deshpande A, et al. Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane Review. Spine (Phila Pa 1976) 2014; 39:556.</a></li><li><a class="nounderline abstract_t">Angst MS, Lazzeroni LC, Phillips NG, et al. Aversive and reinforcing opioid effects: a pharmacogenomic twin study. Anesthesiology 2012; 117:22.</a></li><li><a class="nounderline abstract_t">van Draanen J, Tsang C, Mitra S, et al. Socioeconomic marginalization and opioid-related overdose: A systematic review. Drug Alcohol Depend 2020; 214:108127.</a></li><li><a class="nounderline abstract_t">Lambdin BH, Bluthenthal RN, Wenger LD, et al. Overdose Education and Naloxone Distribution Within Syringe Service Programs - United States, 2019. MMWR Morb Mortal Wkly Rep 2020; 69:1117.</a></li><li><a class="nounderline abstract_t">Dowell D, Ragan KR, Jones CM, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022; 71:1.</a></li><li class="breakAll">FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder. July 23, 2020. United States Food &amp; Drug Administration. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-health-care-professionals-discuss-naloxone-all-patients-when-prescribing-opioid-pain (Accessed on July 23, 2020).</li><li><a class="nounderline abstract_t">Behar E, Rowe C, Santos GM, et al. Primary Care Patient Experience with Naloxone Prescription. Ann Fam Med 2016; 14:431.</a></li><li class="breakAll">Substance Abuse and Mental Health Services Administration. Opioid Overdose Prevention Toolkit. Substance Abuse and Mental Health Services Administration; Rockville, MD, 2013.</li><li><a class="nounderline abstract_t">Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Addiction 2008; 103:979.</a></li><li><a class="nounderline abstract_t">Behar E, Santos GM, Wheeler E, et al. Brief overdose education is sufficient for naloxone distribution to opioid users. Drug Alcohol Depend 2015; 148:209.</a></li><li class="breakAll">Naloxone Nasal Spray prescribing information. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208411lbl.pdf.</li><li><a class="nounderline abstract_t">Davis C, Webb D, Burris S. Changing law from barrier to facilitator of opioid overdose prevention. J Law Med Ethics 2013; 41 Suppl 1:33.</a></li><li class="breakAll">FDA moves quickly to approve easy-to-use nasal spray to treat opioid overdose. United States Food and Drug Administration. https://wayback.archive-it.org/7993/20170722061511/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473505.htm (Accessed on January 11, 2016).</li><li class="breakAll">U.S. Food and Drug Administration. Highlights of Prescribing Information: ZIMHITM (naloxone hydrochloride injection) for intramuscular or subcutaneous use. Department of Health and Human Services, 2021.</li><li class="breakAll">Prescribe to Prevent; Prescribe Naloxone, Save a Life https://prescribetoprevent.org/pharmacists/formulations/ (Accessed on April 13, 2022).</li><li><a class="nounderline abstract_t">Colledge-Frisby S, Rathnayake K, Nielsen S, et al. Injection Drug Use Frequency Before and After Take-Home Naloxone Training. JAMA Netw Open 2023; 6:e2327319.</a></li><li><a class="nounderline abstract_t">Somerville NJ, O'Donnell J, Gladden RM, et al. Characteristics of Fentanyl Overdose - Massachusetts, 2014-2016. MMWR Morb Mortal Wkly Rep 2017; 66:382.</a></li><li><a class="nounderline abstract_t">Giglio RE, Li G, DiMaggio CJ. Effectiveness of bystander naloxone administration and overdose education programs: a meta-analysis. Inj Epidemiol 2015; 2:10.</a></li><li><a class="nounderline abstract_t">Wheeler E, Jones TS, Gilbert MK, et al. Opioid Overdose Prevention Programs Providing Naloxone to Laypersons - United States, 2014. MMWR Morb Mortal Wkly Rep 2015; 64:631.</a></li><li><a class="nounderline abstract_t">Coffin PO, Behar E, Rowe C, et al. Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain. Ann Intern Med 2016; 165:245.</a></li><li><a class="nounderline abstract_t">Enteen L, Bauer J, McLean R, et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health 2010; 87:931.</a></li><li><a class="nounderline abstract_t">Rudolph SS, Jehu G, Nielsen SL, et al. Prehospital treatment of opioid overdose in Copenhagen--is it safe to discharge on-scene? Resuscitation 2011; 82:1414.</a></li><li><a class="nounderline abstract_t">Vilke GM, Sloane C, Smith AM, Chan TC. Assessment for deaths in out-of-hospital heroin overdose patients treated with naloxone who refuse transport. Acad Emerg Med 2003; 10:893.</a></li></ol></div><div id="topicVersionRevision">Topic 99945 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/drugoverdose/index.html" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Opioid overdose. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/drugoverdose/index.html (Accessed on June 19, 2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31167053" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevention of Opioid Overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23372174" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21497898" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27062245" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A pilot randomized clinical trial of an intervention to reduce overdose risk behaviors among emergency department patients at risk for prescription opioid overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29049282" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Behavioral intervention to reduce opioid overdose among high-risk persons with opioid use disorder: A pilot randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30138057" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Modeling Health Benefits and Harms of Public Policy Responses to the US Opioid Epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30138057" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Modeling Health Benefits and Harms of Public Policy Responses to the US Opioid Epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31465320" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Changes in Opioid-Involved Overdose Deaths by Opioid Type and Presence of Benzodiazepines, Cocaine, and Methamphetamine - 25 States, July-December 2017 to January-June 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31465320" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Changes in Opioid-Involved Overdose Deaths by Opioid Type and Presence of Benzodiazepines, Cocaine, and Methamphetamine - 25 States, July-December 2017 to January-June 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25587948" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Trends in opioid analgesic abuse and mortality in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23405084" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Intertwined epidemics: national demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25932890" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Drug-poisoning deaths involving heroin: United States, 2000-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25275328" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Increases in heroin overdose deaths - 28 States, 2010 to 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25275328" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Increases in heroin overdose deaths - 28 States, 2010 to 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33226412" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Polysubstance Involvement in Opioid Overdose Deaths in Adolescents and Young Adults, 1999-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17554010" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Identifying injection drug users at risk of nonfatal overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8997759" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Fatal heroin 'overdose': a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28292769" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12791795" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Heroin overdose: research and evidence-based intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10217555" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fluctuations in heroin purity and the incidence of fatal heroin overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27750104" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Risk of fentanyl overdose among clients of the Sydney Medically Supervised Injecting Centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25581257" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32131996" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24480962" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22713632" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Aversive and reinforcing opioid effects: a pharmacogenomic twin study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32650191" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Socioeconomic marginalization and opioid-related overdose: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32817603" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Overdose Education and Naloxone Distribution Within Syringe Service Programs - United States, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36327391" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36327391" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27621159" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Primary Care Patient Experience with Naloxone Prescription.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27621159" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Primary Care Patient Experience with Naloxone Prescription.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422830" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25595053" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Brief overdose education is sufficient for naloxone distribution to opioid users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25595053" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Brief overdose education is sufficient for naloxone distribution to opioid users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23590737" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Changing law from barrier to facilitator of opioid overdose prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23590737" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Changing law from barrier to facilitator of opioid overdose prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23590737" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Changing law from barrier to facilitator of opioid overdose prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23590737" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Changing law from barrier to facilitator of opioid overdose prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37540514" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Injection Drug Use Frequency Before and After Take-Home Naloxone Training.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28406883" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Characteristics of Fentanyl Overdose - Massachusetts, 2014-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27747742" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effectiveness of bystander naloxone administration and overdose education programs: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26086633" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Opioid Overdose Prevention Programs Providing Naloxone to Laypersons - United States, 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27366987" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20967505" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Overdose prevention and naloxone prescription for opioid users in San Francisco.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21745532" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prehospital treatment of opioid overdose in Copenhagen--is it safe to discharge on-scene?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12896894" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Assessment for deaths in out-of-hospital heroin overdose patients treated with naloxone who refuse transport.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
